Looking Beyond Phase 1 Trials: Situations and Consequences

Friday, May 7, 2021
  • <<
  • >>

In the rush to get a promising treatment into Phase 1 trials quickly and inexpensively, many companies choose a service provider that only has experience in the formulation. While this approach may help with Phase 1 studies, it may hinder further trials and ultimately slow the transition to late-phase and commercial manufacturing causing delays and mounting expenses. A holistic approach to formulation, process development, and manufacturing is preferable, and using a service provider with a full range of product services can ultimately save time and money. In the below infographic, find some potential Phase 1/IND decisions that can cause bottlenecks as you move through clinical trials and into commercial-scale manufacturing.

drug manufacturing infographic process

Download Now

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.